In vivo persistence of chimeric antigen receptor (CAR)-modified T cells correlates with therapeutic efficacy, yet CAR-specific factors that support persistence are not well resolved. Using a CD33-specific CAR in an acute myeloid leukemia (AML) model, we show how CAR expression alters T cell differentiation in a ligand independent manner. Ex vivo expanded CAR-T cells demonstrated decreased naïve and stem memory populations and increased effector subsets relative to vector-transduced control cells. This was associated with reduced in vivo persistence. Decreased persistence was not due to specificity or tumor presence, but to pre-transfer tonic signaling through the CAR CD3ζ ITAMs. We identified activation of the PI3K pathway in CD33 CAR-T cells as responsible. Treatment with a PI3K inhibitor modulated the differentiation program of CAR-T cells, preserved a less differentiated state without affecting T cell expansion, and improved in vivo persistence and reduced tumor burden. These results resolve mechanisms by which tonic signaling of CAR-T cells modulates their fate, and identifies a novel pharmacologic approach to enhance the durability of CAR-T cells for immunotherapy.
Introduction
Human T cells expressing tumor-specific chimeric antigen receptors (CARs) have demonstrated potency in the immunotherapy of acute lymphoblastic leukemia (ALL) and are being assessed for other malignancies [1, 2] . CARs coexpress tumor-specific recognition domains and signaling components triggering T cell activation. CAR therapy for B-cell ALL has improved prognosis for patients with refractory or recurrent disease, and therapeutic T cells expressing anti-CD19 receptors incorporating 4-1BB or CD28 and CD3ζ signaling domains induce high rates of remission [3] .
Preclinical data supports the application of CAR therapy for myeloid neoplasms [4] [5] [6] [7] , yet this is less developed. Our group generated an anti-CD33 CAR through the substitution of the CD19 scFv, present in an anti-CD19-41BB-CD3ζ CAR that is FDA approved for the immunotherapy of pediatric ALL, with a CD33-specific scFv [8] [9] [10] . Whereas the resulting AML-specific CAR-T cells potently targeted tumor lines and primary AML samples ex vivo, inadequate persistence in preclinical models led to incomplete tumor clearance and disease recurrence [7] .
CAR-T cell persistence is associated with efficacy and sustained remission [10] [11] [12] [13] [14] . CAR-T cell differentiation, exhaustion, and metabolic status impact the survival and efficacy of adoptively administered cells [15] [16] [17] [18] [19] . These parameters are related to CAR structure. For instance, spontaneous clustering and tonic signaling in GD2-CD28-CD3ζ CAR-T cells induced early exhaustion, limiting therapeutic efficacy [19] . Replacement of the CD28 domain with 4-1BB reduced but did not eliminate this, indicating that ligandindependent CAR signaling influences T cell state [19] .
In this study, we assessed additional determinants of CAR-T cell durability. We show that tonic CAR signaling during ex vivo T cell expansion rather than specificity or tumor presence leads to inadequate persistence. Signaling through CAR CD3ζ ITAMs led to activation of PI3K signaling and was associated with a more differentiated phenotype. This effect was diminished by PI3K inhibitor treatment during ex vivo expansion, which maintained a less differentiated state and heightened in vivo persistence and anti-tumor efficacy. These results demonstrate how tonic CAR signaling promotes ligand-independent terminal differentiation thereby limiting CAR-T cell survival, and support interventions to improve CAR-T cell survival and function.
Results

CD19 and CD33 CAR-T cells control AML tumor growth
CD33-specific CAR-T cells fail to fully eradicate AML [7] despite the potency of its parental CD19-specific receptor against ALL. We first asked whether ligand specificity played a role. We assessed the ex vivo cytolytic potential of CD33 and CD19 CAR-T cells against an AML cell line that was stably transduced with CD19 to co-express CD33 and CD19 (MOLM-13-CD19). The CARs equivalently redirected CTLs against MOLM-13-CD19 cells, with near complete killing at low E:T ratios ( Supplementary Fig. 1 ).
We next tested the efficacy of CD33-and CD19-specific CARs against AML in vivo. Treatment with either CAR equivalently delayed AML progression relative to vectortransduced control T cells (Fig. 1a) . At day 18, a large tumor burden was detected in the control cohort, and this was substantially reduced with both CD33 and CD19 CAR-T cell therapy (Fig. 1b, c) . Thus, there was no significant difference in anti-AML efficacy of T cells modified with the CD33 or clinically-established CD19 CAR.
Poor CAR-T cell survival is tumor independent
To assess CAR-T cell survival in this AML treatment model, absolute cell numbers were determined. At day 5, control CD8 + T cell numbers were significantly greater than CD33 CAR-T cell numbers (Fig. 2a) . At day 18, while control T cells persisted in all organs, few CAR-T cells were seen (Supplementary Fig. 2A ). CD33 and CD19 CAR-T cells had comparably reduced persistence relative to control T cells in vivo, indicating that CAR specificity did not impact T cell longevity. To assess whether differential persistence resulted from tumor recognition or cell intrinsic effects of CAR expression, equal numbers of CD33-specific CAR and control T cells were co-transferred with or without tumor. Regardless of tumor presence, there were significantly fewer CD8
+ and CD4 + CD33 CAR-T cells than control T cells in the liver and spleen of recipient mice ( Fig. 2b and Supplementary Fig. 2B ). The ratio of control to CD33 CAR-T cells in individual mice was unaltered by the presence of tumor (Fig. 2c) . Thus, the accelerated attrition of (Fig. 3a) . Correspondingly, increased proportions of CD33 CAR-T cells differentiated into T EFF and T EM cells. Moreover, control T cells contained more T SCM cells than CD33 CAR-T cells (Fig. 3b, Supplementary Fig. 3C ).
Transducing sorted naïve CD8
-T cells with CAR likewise resulted in reduction of the T N subset and increased T EM proportions relative to control cells ( Supplementary Fig. 3D ). CD33 CAR-T cells also displayed enhanced expression of exhaustion and activation markers relative to control cells on pre-transfer day 12 ( Supplementary Fig. 3E ). Similar skewing of differentiation was observed during ex vivo expansion of CD19 CAR-T cells (Supplementary Figs. 3F and G).
To further examine the differentiation status of CD33 CAR-T cells, methylation of the IFNγ promoter was assessed. Five CpG sites within this locus are highly methylated in T N cells, and demethylated for rapid expression in memory and effector subsets [21] . Control T cells were more heavily methylated at the IFNγ promoter locus compared to CD33 CAR-T cells (Fig. 3c) , further indicating that CD33 CAR-T cells more readily differentiate into memory or short-lived effector cells.
CAR CD3ζ signaling is responsible for altered T cell differentiation
To determine which CAR signaling domains altered T cell differentiation, we generated constructs in which the signaling motifs of 4-1BB (CD33-41BB), CD3ζ (CD33-ITAM), or both (CD33-41BB-ITAM) were mutated (Supplementary methods). The CD33-ITAM and CD33-41BB-ITAM mutants had differentiation profiles similar to control T cells, with increased proportions of T N cells and reduced T EFF cells relative to CD33 CAR-T cells (Fig. 4a) . Mutation + control T cells to CD33 CAR-T cells with and without tumor, normalized to input ratio. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 of 4-1BB alone did not impact differentiation status. This indicated that CAR CD3ζ ITAM signaling during ex vivo T cell expansion leads to a more effector-differentiated phenotype. The CD33-ITAM mutant also exhibited reduced expression of activation and exhaustion markers relative to CD33 CAR-T cells (Fig. 4b) . Although mutation of the CD3ζ domain produced CAR-T cells that were phenotypically similar to control T cells, this resulted in the abrogation of CAR-T cell activity in vitro (Fig. 4c ).
Pre-transfer differentiation of CD33 CAR-T cells diminishes in vivo persistence
We next analyzed the differentiation status of CD33 CAR-T cells after co-transfer with control T cells. Regardless of tumor presence, both CD8
+ and CD4 + CD33 CAR-T cells showed elevated frequencies of effector subsets while control T cells maintained increased percentages of T N cells (Fig. 5a , b, Supplementary Figs. 4A-C). Therefore, the perturbed subset proportions observed during ex vivo culture are maintained after transfer in vivo. Several studies have associated high frequencies of effector subsets with diminished therapeutic T cell survival [22] [23] [24] . We hypothesized that increased effector differentiation of CD33 CAR-T cells reduces their sustainability in vivo. We evaluated the persistence of sorted CD8 + T N and T EM subsets of CD33 CAR or control T cells. There were no differences between CAR and control groups for T N and T EM cells, and transferred T N cells were better sustained regardless of CAR expression (Fig. 5c ). Therefore poor in vivo persistence of CAR-T cells can be attributed to decreased T N and increased T EM proportions in pre-transfer populations, rather than an effect of the CAR itself on T cell survival after transfer.
CD33 CAR-T cells exhibit a distinct transcriptional profile
To further explore the impact of CAR signaling on T cell differentiation, we analyzed transcriptomes of CD33 CAR and control T cells during ex vivo expansion. Approximately 500 genes were differentially expressed and Ingenuity upstream regulator analysis identified TCR as the top upstream regulator of gene expression changes (P value: 2.71E-38, Activation z-score: 2.695), indicating increased TCR signaling in CD33 CAR relative to control T cells, despite the absence of cognate ligand during culture [25] . Consistently, pathways associated with TCR signaling were Fig. 5A and B). The PI3K/AKT and glycolysis pathways were highly upregulated in CD33 CAR-T cells (Fig. 6a ). These were of interest as PI3K/AKT signaling controls CD8 + T cell differentiation through mTOR-mediated effects on glycolysis [26] . To further assess these pathways, we analyzed the phosphorylation state of downstream targets of PI3K and TCR signaling in T cells 12 days after activation. Constitutive levels of phospho-S6 and 4EBP-1 were higher in CD33 CAR than control T cells (Fig. 6b) . No detectable changes were observed in phospho-AKT or ERK levels ( Supplementary Fig. 5C ). In addition to the constitutive activation seen, CAR-T cells also demonstrated elevations of pS6, 4EBP-1, and pERK relative to controls 10 min after PMA/ionomycin activation, indicating an impact of the CAR after acute stimulation (not shown). These data imply that tonic CAR signaling promotes constitutive activation of some components of the PI3K/AKT pathway and are consistent with persistent ligand-independent activation of TCR CD3ζ signaling through the CAR.
PI3K/AKT signaling drives CD8+ CAR-T cell effector differentiation ex vivo
Constitutive activation of PI3K/AKT/mTOR promotes terminal differentiation of CD8 + T cells, while antagonism promotes memory development [27, 28] . To evaluate the role of PI3K/AKT/mTOR activation in CD33 CAR-T cell differentiation, we added PI3K, AKT, mTOR, or glycolysis inhibitors to pre-transfer CAR-T cell cultures. Treatment with PI3K inhibitors increased T N and T CM percentages relative to untreated CD33 CAR-T cells (Fig. 7a) . Consistent with the role of mTOR in promoting effector differentiation [29] , mTOR inhibitors reduced T EFF percentages. Treatment with AKT or glycolysis inhibitors also increased T N and T CM percentages. While absolute cell numbers were maintained with PI3K inhibitors, they were significantly diminished with all other treatments such that the absolute numbers of T N and T CM cells were decreased relative to untreated CD33 CAR-T cells (Fig. 7b, c) . PI3K inhibition also maintained CCR7 expression on cells undergoing division, such that there was no difference between control and LY294002 treated CAR-T cells (Supplementary Fig. 6 ). Therefore, PI3K inhibitors appear unique in their ability to suppress effector differentiation and increase T N and T CM proportions without diminishing therapeutic T cell expansion.
PI3K blockade enhances CD33 CAR-T cell persistence and reduces tumor burden
The PI3K inhibitor LY294002 was selected for further testing. A concentration of 10 µM optimally impacted T cell differentiation without reducing cell numbers (Supplementary Figs. 7A and B) . PI3K inhibitor-treated and untreated CD33 CAR-T cells were indistinguishable in in vitro killing assays ( Supplementary Fig. 8A ). However, inhibitor-treated CD33 CAR-T cells expressed increased effector molecules relative to untreated CD33 CAR-T cells after co-culture Fig. 8B ).
To determine if PI3K inhibition during ex vivo culture improved in vivo efficacy of CAR-T cells, inhibitor-treated or untreated CD33 CAR-T cells were each transferred into MOLM-13-CD19 tumor-bearing mice. At day 14 after transfer, PI3K inhibition improved the persistence of CD8 + CD33 CAR-T cells in liver and spleen, and resulted in reduced tumor burden in all organs (Fig. 8a) . LY-treated CD33 CAR-T cells also maintained their less differentiated phenotype in vivo, with an increased T N percentage and total cell number ( Fig. 8b and Supplementary Fig. 8 ). Median survival was increased by 3 days in the LY-treated CAR group, relative to the untreated CAR group under these conditions (Fig. 8c) . This modest increase emphasizes the need for further optimization of this approach. These results indicate that PI3K signaling can be targeted to restrain aberrant CAR-T cell activation without impacting 
Discussion
CAR-T cells are effective treatments for CD19
+ leukemias and lymphomas [3] , but their application to other malignancies remains a challenge. CAR-T cell longevity and functional preservation are critical. We used a CD33-specific CAR incorporating an established framework for the 4-1BB-CD3ζ signaling domains to show that in vivo CAR-T cell persistence is limited by tonic signaling through the CAR CD3ζ ITAMs. This trait was acquired during ex vivo expansion and was independent of antigen specificity. CAR-T cells increasingly differentiated into shorterlived effector forms, and PI3K signaling was responsible for altered differentiation and survival. PI3K inhibition improved CAR-T survival and efficacy in vivo. T N and T CM subsets, including a sub-population of T SCM cells, have been associated with enhanced CAR persistence in vivo [16, 17, [30] [31] [32] . We found that tonic CAR signaling during expansion reduced T N /T SCM and increased effector subsets that correlate with poor persistence in vivo. Transferred T N /T SCM cells showed similarly improved persistence relative to T EM cells regardless of the presence of the CAR. Our data implies that reduced CAR-T cell persistence is mediated through alteration of T cell maturation profiles ex vivo and prior to transfer. This was further correlated with enhanced expression of exhaustion and activation markers in pre-transfer CAR-T cells relative to controls.
Disruption of CD3ζ signaling restored the T N :T EM ratio of CD33 CAR-T cells relative to control cells. Disruption of 4-1BB signaling did not alter CAR-T cell differentiation. Therefore, tonic 4-1BB signaling does not produce a noticeable effect on differentiation, or effects of 4-1BB are superseded by CD3ζ signals. Genome-wide transcriptional profiling identified pathways downstream of TCR signaling that were upregulated in CD33 CAR-T cells, most notably the PI3K/AKT/mTOR and glycolytic pathways, which control T cell differentiation, metabolism, and fate [33, 34] . These findings illustrate the relationship between CAR structure and in vivo persistence, and how the therapeutic capacity of CAR-T cells is influenced by ligandindependent alterations in programming.
PI3K signaling may play different roles in CAR-T cell function at different times during manufacture and application. While antigen-dependent PI3K signaling has been NFKBIA  GAB2  NFKB2  ITGA2  EIF4EBP1  NFKBIE  MAP3K8  CDKN1A  HSP90AB1  JAK3  NFKBIB  TP53  AKT3  IKBK3  PIK3CD  CDC37  ITGA4  PPP2R2B  ITGB1   PTGS2   PI3K/AKT PATHWAY   GAPDH  PFKP  TPI1  ALDOA  PKM  GPI  PGAM1  PFKL  ENO1 correlated with increased in vivo efficacy [35] , we show a link between antigen-independent constitutive PI3K activation during ex vivo culture and reduced in vivo persistence. Treatment with a PI3K inhibitor during ex vivo CAR-T cell expansion increased T N /T SCM and T CM populations, and decreased the T EFF population, resulting in improved in vivo persistence and cytokine production. PI3K inhibitor treatment was associated with unperturbed ex vivo CAR-T cell expansion, and can be incorporated into production regimens without adversely impacting yield.
Inhibition of other pathways may similarly alter CAR-T cell differentiation. Treatment of CAR-T cells with BET bromodomain inhibitors, which downregulate c-Mycdependent target genes, resulted in expansion of T N and T CM phenotypes and extended survival in an ALL model [36, 37] . This is consistent with our result in that aberrant PI3K and mTOR signaling may also activate c-Myc resulting in altered metabolism and differentiation [38, 39] . Downstream of PI3K, excessive activation of mTOR leads to increased glycolysis and terminal differentiation [28] . While mTOR and glycolysis inhibition reduced the proportion of T EFF cells, they severely reduced proliferative capacity, making them undesirable targets for use during ex vivo CAR-T cell expansion.
These results have broader implications for CARmediated immunotherapy. CD3ζ is a component of CAR constructs incorporating CD28, 4-1BB and other costimulatory domains, and all CAR constructs undergoing clinical trials [40] , and its impact on T cell differentiation is likely intrinsically linked to signaling essential for CAR-T cell activation. Alternatively, inhibition of PI3K during ex vivo expansion is easily performed, and enhances CAR-T cell quality and in vivo persistence without affecting cell numbers. These findings form a basis for alternative approaches to improve cell-intrinsic features of therapeutic CAR-T cells and enhance the clinical efficacy of cell-based immunotherapeutics for cancer. Cell lines and culture MOLM-13 transduced with firefly luciferase (Dr. Sharyn Baker, SJCRH) was transduced with human CD19 and single cell sorted to isolate stable cell line MOLM-13-CD19. MOLM-13-CD19 and Phoenix-AMPHO cells (ATCC-CRL-3213) were cultured in RPMI-1640 and DMEM (Life Technologies) with 10% FBS (Atlanta Biologicals), 100 U/ml penicillin, 100 μg/ml streptomycin and 292 μg/ml L-glutamine (Life Technologies). + T cells after 4 days of inhibitor treatment, normalized to untreated CAR-T cells. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
Materials and methods
Mice
CAR constructs and retrovirus production
Anti-CD33 [41] and anti-CD19 [42] scFv fragments were cloned in frame with the human CD8 leader sequence, CD8 transmembrane domain, and 41BB-CD3ζ signaling tail in MSCV-IRES-GFP or MSCV-IRES-RFP vectors. Empty vector was used as a negative control. Mutations to signaling domains were introduced by QuikChange mutagenesis (Agilent) (Supplementary methods). Phoenix-AMPHO cells were transfected and supernatant was collected 2-3 days later.
Transduction of human T cells
Leukocytes were isolated from apheresis rings by density gradient. T cells were isolated using the human Pan T Cell Isolation Kit (Miltenyi) and stimulated with anti-human CD3 and CD28 (eBioscience) in RPMI with IL-2 for 24 h prior to transduction on RetroNectin-coated plates (TaKaRa). Viral supernatant from transfected Phoenix-AMPHO cells was used for transduction. GFP + or RFP + cells were sorted and expanded in culture with IL-2 for 5-7 days. All experiments were repeated with control and CAR-T cells generated from at least 2 donors.
Inhibitor treatment
CD33 CAR or control T cells were labeled with CellTrace Violet 5 days after activation and treated with 100 U/ml IL-2 and small-molecule inhibitors of PI3K (LY294002, 10 μM; IC87114, 10 μM; Cell signaling) [43] , AKT (API-2, 1 μM, Abcam), mTOR (rapamycin, 50 nM; PP242, 1 μM, Abcam), or glycolysis (DCA, 10 mM, Sigma) every other day for 4 days, then analyzed in triplicate by flow cytometry or used, in the absence of CellTrace Violet labeling, in adoptive immunotherapy experiments. 
Flow cytometry
Immunophenotypic analysis was performed with the indicated antibodies (supplementary methods). Non-viable cells were excluded with 7AAD. An LSR Fortessa (BD Biosciences) was used with FlowJo 9.6.6 software (Treestar) for analysis. Flow sorting was performed with a Reflection (iCyt) cytometer (Sony Biotechnology).
Co-culture killing assays
CAR or control T cells were incubated with MOLM-13-CD19 cells in duplicate as indicated and analyzed by flow cytometry at 24-48 h. Cell numbers were normalized to TrucountTM beads (BD Biosciences).
Adoptive immunotherapy
All experiments were performed with at least 5 mice per group without randomization or blinding. 1 × 10 6 MOLM-13-CD19 cells were administered i.v. and 6 × 10 6 CAR or empty-vector transduced control T cells were administered retro-orbitally the same day. For experiments with LYtreated CD33 CAR-T cells, 3 × 10 6 treated or untreated CAR T cells were administered reto-orbitally the same day as tumor. Mice were imaged using the Xenogen imaging system (Caliper Life Science). Organs were harvested as indicated after transfer and analyzed by flow cytometry. 
Bisulfite sequencing of human IFNγ promoter
Naïve CD8 + CD45RA + CD45RO -CCR7 + CD95 -T cells were sorted from 3 separate donor samples and transduced with CD33 CAR or control vector. Genomic DNA was isolated 9 days after activation and subjected to bisulfite sequencing as previously described [21] .
RNA sequencing
RNA was extracted from CD33 CAR or control T cells generated from 3 separate donors 12 days after activation using TRIzol (Life Technologies). Paired-end sequencing was performed and analyzed by Ingenuity Pathway Analysis (QIAGEN) (Supplementary methods). All data are available at the Gene Expression Omnibus (GEO), accession code GSE93386. 
Statistical analysis
